Back to Search
Start Over
Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa
- Source :
- DERMATOLOGY, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname
- Publication Year :
- 2020
- Publisher :
- KARGER, 2020.
-
Abstract
- Adalimumab is the only approved biological therapy for hidradenitis suppurativa (HS). The last published recommendations support the use of other off-label biologic therapies. We report on a multicentric retrospective review of patients with HS treated with an ustekinumab dosing schedule of intravenous infusion adjusted by weight, followed by a subcutaneous maintenance dose of 90 mg every 8 weeks, as recently approved for Crohn’s disease. The minimal follow-up period required for inclusion was 16 weeks. A total of 14 patients from six hospitals were included. In 50% of the treated patients, therapeutic outcomes, measured by means of the Hidradenitis Suppurativa Clinical Response (HiSCR) and decrease of Dermatology Life Quality Index (DLQI) and visual analog scale (VAS) of pain, were reached at week 16. In 71.42% of patients DLQI and VAS of pain improved, irrespective of achievement of HiSCR. Two patients abandoned treatment due to lack of efficacy or patient preferences. No ustekinumab-related adverse effects were reported. The results are limited by the retrospective nature of the study, the short follow-up period, and the small patient number. This therapeutic regime proved to be safe and showed moderate efficacy in treating HS with failure to previous biologic therapy. Ideally, the efficacy of ustekinumab in HS should be tested in randomized and controlled clinical trials.
- Subjects :
- Adult
Male
medicine.medical_specialty
Hidradenitis
Visual analogue scale
Intravenous infusion
Injections, Subcutaneous
Dermatology
Severity of Illness Index
030207 dermatology & venereal diseases
03 medical and health sciences
Young Adult
0302 clinical medicine
Internal medicine
Ustekinumab
Adalimumab
medicine
Humans
Hidradenitis suppurativa
Infusions, Intravenous
Retrospective Studies
business.industry
Maintenance dose
Dermatology Life Quality Index
Middle Aged
medicine.disease
Hidradenitis Suppurativa
Clinical trial
Treatment Outcome
030220 oncology & carcinogenesis
Female
Dermatologic Agents
business
medicine.drug
Subjects
Details
- ISSN :
- 10188665
- Database :
- OpenAIRE
- Journal :
- DERMATOLOGY, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname
- Accession number :
- edsair.doi.dedup.....b7d4707806cc3aa5041db837a36bf5f3